Literature DB >> 11215691

Synthetic vitreous fibers: a review of toxicology research and its impact on hazard classification.

T W Hesterberg1, G A Hart.   

Abstract

Because the inhalation of asbestos, a naturally occurring, inorganic fibrous material, is associated with lung fibrosis and thoracic cancers, concerns have been raised about the possible health effects of synthetic vitreous fibers (SVFs). SVFs include a very broad variety of inorganic fibrous materials with an amorphous molecular structure. Traditionally, SVFs have been divided into three subcategories based on composition: fiberglass, mineral wool (rock, stone, and slag wools), and refractory ceramic fiber. For more than 50 years, the toxicologic potential of SVFs has been researched extensively using human epidemiology and a variety of laboratory studies. Here we review the research and its impact on hazard classification and regulation of SVFs. Large, ongoing epidemiology studies of SVF manufacturing workers have provided very little evidence of harmful effects in humans. Several decades of research using rodents exposed by inhalation have confirmed that SVF pulmonary effects are determined by the "Three D's", fiber dose (lung), dimension, and durability. Lung dose over time is determined by fiber deposition and biopersistence in the lung. Deposition is inversely related to fiber diameter. Biopersistence is directly related to fiber length and inversely related to fiber dissolution and fragmentation rates. Inhaled short fibers are cleared from the lung relatively quickly by mobile phagocytic cells, but long fibers persist until they dissolve or fragment. In contrast to asbestos, most of the SVFs tested in rodent inhalation studies cleared rapidly from the lung (were nonbiopersistent) and were innocuous. However, several relativley biopersistent SVFs induced chronic inflammation, lung scarring (fibrosis), and thoracic neoplasms. Thus, biopersistence of fibers is now generally recognized as a key determinant of the toxicologic potential of SVFs. In vitro dissolution of fibers in simulated extracellular fluid correlates fairly well with fiber biopersistence in the lung and pulmonary toxicity, but several exceptions suggest that biopersistence involves more than dissolution rate. Research demonstrating the relationship between biopersistence and SVF toxicity has provided a scientific basis for hazard classification and regulation of SVFs. For a nonhazardous classification, legislation recently passed by the European Union requires a respirable insulation wool to have a low lung-biopersistence or be noncarcinogenic in laboratory rats. U.S. fiberglass and mineral wool industries and the Occupational Health and Safety Administration (OSHA) have formed a voluntary Health and Safety Partnership Program (HSPP) that include: a voluntary permissible exposure level (PEL) in the workplace of 1 fiber/cc, a respiratory protection program for specified tasks, continued workplace air monitoring, and, where possible, the development of fiber formulations that do not persist in the lung. RCF manufacturers have implemented a Product Stewardship Program that includes: a recommended exposure guideline of 0.5 fibers/cc; a 5-year workplace air monitoring program; and research into the development of high-temperature-resistant, biosoluble fibers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11215691     DOI: 10.1080/20014091111668

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  19 in total

1.  Behavior of rock wool in lungs after exposure by nasal inhalation in rats.

Authors:  Yuichiro Kudo; Yoshiharu Aizawa
Journal:  Environ Health Prev Med       Date:  2009-05-26       Impact factor: 3.674

2.  Clearance of carbon nanotubes in the human respiratory tract-a theoretical approach.

Authors:  Robert Sturm
Journal:  Ann Transl Med       Date:  2014-05

Review 3.  People, planet and profit: Unintended consequences of legacy building materials.

Authors:  Anthony T Zimmer; HakSoo Ha
Journal:  J Environ Manage       Date:  2017-12-15       Impact factor: 6.789

Review 4.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

Review 5.  Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos.

Authors:  Brooke T Mossman; Morton Lippmann; Thomas W Hesterberg; Karl T Kelsey; Aaron Barchowsky; James C Bonner
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  Behavior of new type of rock wool (HT wool) in lungs after exposure by nasal inhalation in rats.

Authors:  Yuichiro Kudo; Kaori Shibata; Takeo Miki; Mio Ishibashi; Kaori Hosoi; Toshihiko Sato; Norihiko Kohyama; Yoshiharu Aizawa
Journal:  Environ Health Prev Med       Date:  2005-09       Impact factor: 3.674

7.  Case report: analytical electron microscopy of lung granulomas associated with exposure to coating materials carried by glass wool fibers.

Authors:  Angela S Ferreira; Valéria B Moreira; Marcos César S Castro; Porfírio J Soares; Eduardo Algranti; Leonardo R Andrade
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

8.  Case studies: evaluation of cut-resistant sleeves and possible fiberglass fiber shedding at a steel mill.

Authors:  Diana M Ceballos; Loren C Tapp; Douglas M Wiegand
Journal:  J Occup Environ Hyg       Date:  2014       Impact factor: 2.155

9.  Comparative dissolution of electrospun Al2O3 nanofibres in artificial human lung fluids.

Authors:  Hyeon Ung Shin; Aleksandr B Stefaniak; Nenad Stojilovic; George G Chase
Journal:  Environ Sci Nano       Date:  2015-04-27

10.  Effects of rock wool on the lungs evaluated by magnetometry and biopersistence test.

Authors:  Yuichiro Kudo; Makoto Kotani; Masayuki Tomita; Yoshiharu Aizawa
Journal:  J Occup Med Toxicol       Date:  2009-03-27       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.